Lirilumab
Sign in to saveLirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2/3.
~1 min read
Encyclopedic overview
2 sectionsContents
- Clinical trials
- References
Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2/3.
This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb.
Excerpted from Wikipedia’s “Lirilumab” article, available under the CC BY-SA 4.0 licence.